Company Deep Dive
Read the full research report: business segments breakdown, earnings transcripts review, management credibility analysis, competitive landscape, and scenarios.
IRWD
STRONG BUYIronwood Pharmaceuticals, Inc. · Healthcare · United States · $680M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Ironwood Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. The company's flagship product, LINZESS/CONSTESS, is a market leader for irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Ironwood's competitive edge is derived from its proven commercialization capabilities, a pipeline of novel GI candidates, and strategic collaborations that broaden its reach in this underserved therapeutic area.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 410.6M | 442.7M | 351.4M | 296.2M | -10.3% | 361.5M | 459.5M | 478.4M | 27.1% |
| EPS | 1.13 | -6.45 | 0.01 | 0.15 | -49.0% | 0.61 | 1.09 | 1.44 | 209.8% |
| Shares | 154.0M | 156.4M | 160.2M | 163.1M | +5.9% | 164.6M | — | — | — |
| Debt | 415.9M | 715.5M | 599.5M | 597.8M | 12.9% | 597.4M | — | — | — |
| Equity | 652.4M | -346.3M | -301.3M | -261.8M | — | — | — | — | — |
| Op CF | 273.8M | 183.4M | 103.5M | 127.0M | -22.6% | 112.2M | — | — | — |
| Inv CF | -0.1M | -1.0B | -0.1M | -34.0K | — | — | — | — | — |
| Fin CF | -237.6M | 277.2M | -107.0M | 0.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IRWD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IRWD | Ironwood Pharmaceuticals, Inc.(you) | $680M | 98 | STRONG BUY |
| COLL | Collegium Pharmaceutical, Inc. | $1.2B | 96 | STRONG BUY |
| PCRX | Pacira BioSciences, Inc. | $993M | 91 | STRONG BUY |
| GTII.CN | Green Thumb Industries Inc. | $1.7B | 94 | STRONG BUY |
| ANIP | ANI Pharmaceuticals, Inc. | $1.9B | 97 | STRONG BUY |
| EBS | Emergent BioSolutions Inc. | $440M | 85 | STRONG BUY |
| BCRX | BioCryst Pharmaceuticals, Inc. | $2.5B | 96 | STRONG BUY |
| AMPH | Amphastar Pharmaceuticals, Inc. | $960M | 73 | BUY |
| SIGA | SIGA Technologies, Inc. | $281M | 81 | STRONG BUY |
| PAHC | Phibro Animal Health Corporation | $1.3B | 73 | BUY |
Peer medians: ROE -21.2% · P/E 27.3x · Gross margin 44.3%